A genetic study published in Science Advances linked a subtype of primary idiopathic hyperhidrosis to a neurocutaneous NaV1.8 channelopathy. Researchers from Vrije Universiteit Brussel and collaborators analyzed DNA from more than 180 patients and identified Nav1.8 ion channel defects consistent with an overactive nerve signaling state that drives excessive sweating. The team developed a mouse model using a genetic approach aligned to the human defect, paired with a microscopic droplet counting method for paw sweating. Blocking the overactive nerve signal reduced symptoms and the effects were described as reversible. The paper highlights a move away from treating hyperhidrosis purely as a skin complaint and toward addressing upstream neural signaling that controls sweat gland activity. It also suggests the feasibility of repurposing or refining existing medicines targeting nerve excitability pathways for specific genetic subgroups. For the biotech industry, the clinical relevance lies in target definition: a defined ion channel mechanism can support biomarker-based patient selection and clearer pharmacology strategies.